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ABSTRACT 
Disseminated Mycobacterium avium complex (DMAC) infec- 
tion is a common complication of advanced HIV disease, and 
is an independent predictor of mortality. The clinical features of 
DMAC infection are fever, weight loss, abdominal pain, anemia, 
elevated serum alkaline phosphatase, and elevated serum lac- 
tate dehydrogenase. The diagnosis is made by blood cultures; 
clinical diagnosis is unreliable. Chemoprophylaxis of DMAC 
infection with azithromycin is recommended when the CD4 
lymphocyte count is below 50 cells/mm3. Established DMAC 
infection is treated with clarithromycin plus ethambutol, unless 
the isolate is macrolide-resistant, in which case the optimal 
therapy is uncertain. Highly active antiretroviral therapy is impor- 
tant in both prevention and treatment of DMAC infection. 
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Organisms in the Mycobacterium avium complex (MAC) 
are common environmental bacteria of relatively low vir- 
ulence in immunocompetent individuals. Human infec- 
tion due to MAC results in three distinct synd:romes: (1) 
cervical lymphadenitis, seen primarily in otherwise 
healthy children less than 5 years of age; (2) pulmonary 
disease, which can resemble tuberculosis or bronchiec- 
tasis; and (3) disseminated disease in the imrnunocom- 
promised. Disseminated MAC (DMAC) disea:se occurs 
almost exclusively in advanced human immuno~deficiency 
virus (HIV) disease, but also occurs rarely among other 
severely immunocompromised individuals. l For reasons 
that are unclear, MAC pulmonary disease is ra.re in HIV- 
infected individuals. This article is restricted to DMAC 
infection complicating acquired immunodeficiency 
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syndrome (AIDS), with an emphasis on prophylaxis and 
therapy. 
THE ORGANISM 
Mycobacterium avium complex organisms are non-chro- 
mogenic slow-growing mycobacteria classified in Run- 
yon group III.2 The complex consists of three species, 
M. avium, M. intracellulare, and M. lepraemurium, the 
last of which is strictly an animal pathogen. Mycobac- 
terium avium consists of three subspecies, of which only 
M. avium subspecies avium is a human pathogen. His- 
torically, M. avium and M. intracellulare organisms have 
been subtyped by serotyping; however, serotyping is prob- 
lematic because the antisera are not widely available and 
not all MAC strains are typeable. More recently, DNA-based 
typing by restriction fragment length polymorphism 
(RFLP) has supplanted serotyping for purposes of epi- 
demiologic studies.3 
Pulmonary disease due to MAC in HIV-uninfected 
individuals is caused by M. avium and M. intracellulare 
in relatively similar proportions, but MAC disease in HIV- 
infected individuals is nearly always attributable to M. 
avium.* A possible explanation for this discrepancy is 
the observation by Crowle et al that macrophages from 
HIV-infected individuals are more susceptible to infec- 
tion with M. avium than M. intracellulare, whereas 
macrophages from individuals without HIV infection are 
equally susceptible to infection with both species.j 
Epidemiology 
Most of the data regarding the epidemiology of DMAC 
infection antedate the era of highly active antiretroviral 
therapy (FIAAR’I). Disseminated MAC infection is the most 
common bacterial opportunistic infection in persons with 
HIV infection. In the Adolescent and Adult Spectrum of 
Disease Study,6 DMAC infection was second in incidence 
only to Pneumocystis carinii pneumonia (PCP) among 
all HIV-related complications. A wide variety of incidence 
rates of DMAC infection have been reported among dif- 
ferent populations of HIV-infected persons. However, the 
most reliable data come from prospective studies with 
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intensive surveillance. Among 1006 individuals with a 
previous AIDS-defining event, who were prospectively 
followed with monthly mycobacterial blood cultures, the 
incidence of MAC bacteremia was 20% per year.’ How- 
ever, a previous AIDS-defining event is a known risk fac- 
tor for DMAC infection,8s9 and the risk of DMAC infection 
in individuals who have not previously experienced an 
AIDS-defining event is lower. The major risk factor for 
the development of DMAC infection is CD4 lymphocy- 
topenia. ‘s8 Nonuse of antiretroviral therapy also is asso- 
ciated with the development of DMAC infection,8x9 and 
recently it has been demonstrated that the risk of DMAC 
infection is higher in whites and lower in injection drug 
users9 There is no difference in the incidence of DMAC 
infection between males and females9 and it appears that 
children are at similar risk for DMAC infection.10 
The incidence of DMAC infection in developing 
countries is considerably less than in developed coun- 
tries.“,r2 This may be due, at least in part, to the demon- 
stration that a prior history of tuberculosis reduces the 
subsequent risk of developing DMAC infection.9 
Pathogenesis 
Mycobacterium avium complex organisms have been 
isolated from a variety of environmental sources, includ- 
ing water, soil, birds, pigs, and cattle.2 The exact route of 
acquisition from environmental sources to humans is 
uncertain, but indirect evidence favors acquisition 
through either the gastrointestinal or respiratory tracts. 
Among HIV-infected individuals without evidence of 
DMAC infection from whom gastrointestinal and respi- 
ratory samples grow MAC, approximately 50 to 60% will 
develop DMAC infection within 1 year. 13-li However, most 
individuals with DMAC do not have positive antecedent 
stool or respiratory tract samples.16 Mycobacterium 
avium complex has been isolated from hospital water 
supplies, l7 and nosocomial transmission of MAC from 
hospital water supplies to HIV-infected individuals has 
been described in two American hospitals.18 
A critical requirement of the pathogenesis of DMAC 
infection is severe CD4 lymphocyte depletion. In most 
clinical trials, the median CD4 lymphocyte count at the 
time of diagnosis of DMAC infection is 10 to 15 
cells/mm3, and it is uncommon for the CD4 lymphocyte 
count to exceed 50 cells/mm3.h In a prospective study 
wherein patients had monthly mycobacterial blood cul- 
tures and CD4 lymphocyte counts performed every 3 
months,19 the PO-day risk of MAC bacteremia shows the 
clear relation of increasing risk with diminishing CD4 
lymphocyte count (Table 1). 
Whether MAC enters the body through the gas- 
trointestinal or the respiratory tract, the mechanism of 
subsequent dissemination is uncertain. Although any 
organ can be infected, the sites where organisms are most 
Table 1. Risk of MAC Bacteremia in the 90-Day 
Period following Selected CD4 Lymphocyte Count Ranges 
in HIV-Infected Adults Not Receiving MAC Prophylaxis 
or Highly Active Antiretroviral Therapy 
CD4 Range Number of 
(ce//s/mnP) Patients 
SO-Day incidence 
of MAC Bacteremia (%) 
O-20 521 8.6 
21-40 291 6.2 
41-60 185 3.8 
61-80 91 4.4 
81-100 58 1.7 
101-120 47 0 
Adapted from Cameron et al.lg 
frequently found include the blood, bone marrow, lymph 
nodes, gastrointestinal tract, liver, and spleen.z.20 
CLINICAL FEATURES OF DISSEMINATED 
Mycobacterium avium COMPLEX INFECTION 
Many descriptive studies have reported the symptoms 
and signs observed in patients with DMAC infection; how- 
ever, it has been unclear which of these clinical features 
are attributable to MAC, and which are attributable to 
HIV infection or the many other complications of HIV 
infection that occur simultaneously in individuals with 
extremely low CD4 lymphocyte counts. Recently, Gordin 
et al performed a case-control study of placebo recipi- 
ents in a randomized clinical trial evaluating prophylac- 
tic therapy for MAC bacteremia.21 Individuals who 
subsequently developed MAC bacteremia were the cases 
in the study and for each case, two individuals who did 
not subsequently develop MAC but had similar CD4 lym- 
phocyte counts (*lo cells/mm3) at baseline were 
selected as controls. At the time after enrollment when 
MAC disease occurred in the cases, the features that were 
statistically more common in those with MAC disease 
were weight loss, fever, abdominal pain, lower Karnofsky 
score, lower hemoglobin count, elevated serum alkaline 
phosphatase, and elevated serum lactate dehydrogenase 
(LDH). The presence of night sweats and fatigue were 
more common in cases, approaching statistical signifi- 
cance (0.05 < P < 0.1). However, fatigue, leukocyte count, 
platelet count, serum bilirubin, and serum aminotrans- 
ferase levels did not differ between the groups. Of the 
clinical features of DMAC infection, weight loss appeared 
first, with a mean difference in weight of 5.5 kg 3 months 
prior to DMAC infection. Fever was the next feature to 
develop, occurring in 40% of cases versus 24% of controls 
(P = 0.02) 2 months prior to DMAC infection. One month 
prior to DMAC infection, there was a small but statistically 
significant difference in hemoglobin count (only 1.1 g/dL) 
and LDH. In a smaller study, fever, anemia, weight loss, diar- 
rhea, and elevated serum alkaline phosphatase were the 
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clinical features statistically significantly associated with 
DMAC infection2* 
DZAGNOSIS 
The clinical features of DMAC infection are not suffi- 
ciently specific to permit accurate clinical diagnosis. Even 
among the clinical features that are statistically more fre- 
quent among patients with DMAC infection, the differ- 
ence in prevalence from controls is not great. For 
example, in the study described above, fever was reported 
in 48% of cases versus 26% of controls and atbdominal 
pain was reported in 23% of cases and 13% of contro1s21 
Hence, the diagnosis of DMAC infection can only be made 
by using laboratory tests. Laboratory investigations for 
DMAC infection should be considered in any HIV-infected 
individual with a CD4 lymphocyte count below 50 
cells/mm3 who has one or more of the features noted 
above. Clearly, the lower the CD4 count and the more 
clinical features present, the greater the likelihood of 
DMAC infection. 
The preferred investigation for DMAC infection is a 
mycobacterial blood culture. Several laboratory tech- 
niques can be used, of which the BACTECTM radiometric 
method (Becton Dickinson Microbiology Systems, 
Mississauga, Ontario, Canada) and the isolator lysis- 
centrifugation techniques are the most commonly used.2 
Although these cultures are incubated for at least 6 
weeks, most cultures that ultimately grow MAC do so 
within 14 days in the BACTEC system. A single blood cul- 
ture is sufficient, because MAC bacteremia is continuous, 
and additional blood cultures add little to the sensitivity 
of a single sample. There have been a few reports of pos- 
itive cultures from bone marrow when blood cultures 
have been negative, but this is a relatively rare event. 
Occasionally, bone marrow examination results in a same- 
day diagnosis, because of a positive direct acid-fast stain. 
Occasionally, the diagnosis is made by biopsy of a lymph 
node or a duodenal nodule at endoscopyz3 Cultures of 
stool and respiratory secretions, when positive, indicate 
a significant risk of DMAC infection, but do not confirm 
disseminated infection. 
Once mycobacterial growth is detected, it is critical 
for the laboratory to speciate the organism promptly, 
largely for the purposes of excluding tuberculosis. Com- 
mercially available DNA probes exist for both &Qcobac- 
terium tuberculosis complex and MAC, and are 
commonly used by most laboratories. The use of DNA 
probes usually ensures that speciation occurs within 48 
hours of the initial detection of mycobacterial growth. 
DNA probes also are useful for differentiating between 
MAC and M. tuberculosis complex when applied 
directly to samples of respiratory secretions that are 
smear-positive for acid-fast bacilli; but they are not reli- 
able for samples that are smear-negative. 
CLINICAL SIGNIFICANCE OF DISSEMINATED 
Mycobacterium avium COMPLEX 
In the early years of the HIV epidemic, there was debate 
as to whether DMAC infection was a significant contrib- 
utor to mortality in HIV, or whether it was merely a 
marker that “the end was neaY2* Subsequently, several 
studies demonstrated that DMAC infection is an inde- 
pendent predictor of mortality, even after adjustment for 
CD4 lymphocyte count. 8,25 Furthermore, several retro- 
spective studies and one prospective, nonrandomized 
study demonstrated increased survival associated with 
antimycobacterial therapy, providing further evidence 
that DMAC infection was responsible for shortened sur- 
viva1.14J6-29 Disseminated Mycobacterium avium com- 
plex infection also results in considerable morbidity, as 
evidenced by lower Karnofsky performance scorc,z1 
poorer quality of life assessments, weight loss, and ane- 
mia that sometimes necessitates transfusions. 
PREVENTION 
Because of the ubiquity of MAC organisms in the envi- 
ronment, it is not possible to avoid environmental expo- 
sure to MAC. Nevertheless, some individuals with 
advanced HIV disease may choose to consume only dis- 
tilled water, not only for the theoretic possibility that 
MAC exposure will be reduced, but also to prevent other 
waterborne infections, such as cryptosporidiosis. 
Although this approach may be reasonable, there are inad- 
equate data to support routine recommendation of this 
strategy. 
Because of the high incidence of MAC infection in a 
well-defined subset of HlV-infected individuals and the 
proven success of chemoprophylaxis for PCP it is not 
surprising that studies were undertaken to evaluate 
chemoprophylaxis of MAC. The first such study evalu- 
ated clofazimine in a dosage of 50 mg once daily and 
found no evidence that clofazimine was effective.3o Sub- 
sequently, two identically designed placebo-controlled tri- 
als demonstrated that rifabutin reduced the incidence of 
MAC bacteremia 55% by intent-to-treat analysis and 60% 
by efficacy analysis.31 Follow-up of the study participants 
demonstrated a survival advantage in individuals ran- 
domized to rifabutin.32 
The newer macrolides, clarithromycin and azithro- 
mycin, are both potent against MAC in vitro, and each of 
these drugs has been compared against both placebo and 
rifabutin for the prevention of MAC infection. In a 
placebo-controlled trial, clarithromycin, 500 mg twice 
daily, resulted in a 69% reduction in the incidence of MAC 
bacteremia, and was associated with improved survival.33 
In another placebo-controlled study, azithromycin, 
1200 mg once weekly, reduced the incidence of MAC 
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infection by 59% in an intent-to-treat analysis and 72% in 
the on-therapy analysis. 34 This study did not demonstrate 
a survival advantage in azithromycin recipients, probably 
owing to the small size of the study Both clarithromycin 
and azithromycin have been shown to be more effective 
than rifabutin for the prevention of MAC bacteremia, 
although no survival advantage of macrolides over 
rifabutin has been demonstrated.35,36 
Clinical trials also have evaluated combination pro- 
phylaxis with rifabutin plus a newer macrolide. The com- 
bination of azithromycin plus rifabutin was more effective 
than either agent alone,j6 whereas the combination of 
clarithromycin plus rifabutin was no better than 
clarithromycin monotherapy, the better of the two indi- 
vidual agents. The probable explanation for the discrep- 
ancy between these trials relates to a two-way drug 
interaction between clarithromycin and rifabutin. By 
inducing hepatic microsomal enzymes, rifabutin reduces 
the serum concentration of clarithromycin by approxi- 
mately half.37,38 Furthermore, clarithromycin inhibits the 
cytochrome P-450 3A pathway by which rifabutin is 
metabolized, and this results in a significant increase in 
the serum concentrations of both rifabutin and its 
desacetyl metabolite.38z39 In contrast, there is no significant 
drug interaction between rifabutin and azithromycin.39 
On the basis of these data, the United States Public 
Health Service/Infectious Diseases Society of America 
Guidelines for the Prevention of Opportunistic Infection 
in Persons Infected with Human Immunodeficiency Virus 
were revised to recommend that a macrolide is the pre- 
ferred prophylaxis for MAC infection, and that prophy- 
laxis should be administered when CD4 lymphocyte 
counts fall below 50 cells/mm3.40 Although the combi- 
nation of azithromycin and rifabutin is more effective,36 
the added cost and greater toxicity of this regimen con- 
troverted the recommendation of this regimen as the pro- 
phylaxis of choice. 
Compared with clarithromycin, azithromycin offers 
the advantage of a more convenient dosing schedule 
(once weekly vs. twice daily), a considerably lower price, 
and less potential for drug interactions with other impor- 
tant drugs that are metabolized through the cytochrome 
P-450 3A pathway,*l principally HN protease inhibitors 
and non-nucleoside reverse transcriptase inhibitors. 
Azithromycin has been found to be the most cost effec- 
tive prophylaxis for MAC in several ana1yses.42-44 Another 
reason why azithromycin may be preferable to clar- 
ithromycin for MAC prophylaxis is that the evidence to 
date suggests that azithromycin is less likely to induce 
macrolide-resistant MAC. In the placebo-controlled trial of 
azithromycin prophylaxis, none of the five isolates from 
the patients who failed azithromycin prophylaxis were 
resistant to either azithromycin or clarithromycin.34 In 
the study, which compared azithromycin to rifabutin or 
the combination of the two, only 2 of 18 isolates (11%) 
from patients who failed prophylaxis with azithromycin 
(with or without rifabutin) were azithromycin resistant.36 
As expected, these two isolates were also cross-resistant 
to clarithromycin. 36 In contrast, 11 of 19 (58%) isolates 
from individuals on clarithromycin prophylaxis were clar- 
ithromycin resistant.33 If the two transient positive cul- 
tures at week 1 and one patient who developed MAC 
bacteremia 112 days after discontinuing clarithromycin 
are excluded, then 11 of 16 (69%) isolates were highly 
resistant to clarithromycin. For these reasons, this author 
recommends azithromycin, 1200 mg once weekly, as the 
regimen of choice for MAC prophylaxis. 
It is currently recommended that a baseline mycobac- 
terial blood culture be collected prior to initiating MAC 
prophylaxis.4o This recommendation is presumably based 
on the observation that 2 to 3% of participants in clini- 
cal trials evaluating MAC prophylaxis have positive blood 
culture for MAC in the absence of symptoms.31s33-36 
Whether it is cost effective to perform baseline blood 
cultures with only a 2 to 3% positivity rate has not been 
evaluated. 
THERAPY 
Several clinical trials have been conducted in individuals 
who have not been treated previously and who have not 
received macrolide prophylaxis. Clarithromycin was eval- 
uated as monotherapy in a pilot study and was found to 
result in blood sterilization in a majority of individuals.45 
Unfortunately, when monotherapy was continued, a large 
proportion of individuals developed relapse of bac- 
teremia, invariably with strains exhibiting high-level clar- 
ithromycin resistance. *Key Resistance occurred as early as 
8 weeks and at a median of 16 weeks,45 but was largely 
dependent on the baseline mycobacterial load. The higher 
the baseline mycobacterial load, the longer it took to 
achieve blood sterilization and the shorter the duration 
of remission prior to relapse with clarithromycin-resis- 
tam bacteremia.46 The value of clarithromycin as an essen- 
tial component of combination therapy was clearly 
demonstrated in a Canadian, multicenter, randomized clin- 
ical trial comparing the three-drug regimen of clar- 
ithromycin, ethambutol, and rifabutin to a four-drug, 
nonmacrolide-containing regimen of rifampin, ethambu- 
tol, clofazimine, and ciprofloxacin,47 a regimen that was 
first evaluated by the California Collaborative Treatment 
Group,48 and recommended as a standard of care in 
1991.*9z50 This study clearly demonstrated that the 
clarithromycin-containing regimen was associated with 
significantly greater and more rapid rates of blood culture 
sterilization (69% vs. 29% by intent-to-treat analysis; 78% 
vs. 40% among those on treatment for at least 4 weeks) 
and was associated with a survival advantage.47 
Subsequently, other clinical trials have assessed the 
role of specific components of therapy. There is now 
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clear evidence that clofazimine is not helpful in treating 
MAC disease. As noted above, clofazimine was ineffective 
for prophylaxis of MAC infection.30 In a pilot study of 
monotherapy, clofazimine did not reduce the level of 
mycobacteremia. 51 Chaisson et al conducted a random- 
ized trial of patients with MAC bacteremia, all of whom 
received clarithromycin and ethambutol.j2 These patients 
were randomly assigned to receive clofazimine or placebo 
as a third agent. The study found that the rates of blood 
culture sterilization were similar in the two groups, but 
that mortality was greater in clofazimine recipients5’ This 
study suffered from the misfortune that patients assigned 
to the clofazimine arm of the trial had a significantly 
higher level of bacteremia at enrollment, despite random 
allocation. Nevertheless, in an analysis that adjusted for 
baseline level of mycobacteremia, greater mortality among 
clofazimine recipients remained.j’ In another study, May 
et al found that the combination of clarithromycin, etham- 
butol, and rifabutin was significantly more effective in 
preventing relapse of mycobacteremia than a regimen of 
clarithromycin and clofazimine, despite similar initial 
blood sterilization rates.53 
The important role of ethambutol in preventing or 
delaying the emergence of clarithromycin resistance has 
been demonstrated in several trials. Dube et al conducted 
a trial in which patients with MAC bacteremia all received 
clarithromycin plus clofazimine and were randomly allo- 
cated to receive ethambutol or no third drug.54 Blood 
sterilization occurred in 69% of both groups, but there 
was a significant difference in the risk of relapse, which 
at 36 weeks was 68% in the two-drug arm but only 12% 
among those receiving ethambutol (P = 0.004). All relapse 
isolates were resistant to clarithromycin in both treat- 
ment arms. The study of May et al also supports the role 
of ethambutol (with rifabutin) in reducing the risk of 
clarithromycin-resistant relapse,53 as does the study of 
Shafran et a14’ which found no relapse in the first 16 
weeks of treatment with a combination of clarithromycin, 
ethambutol, and rifabutin. 
The trials to date underscore the pivotal roles of clar- 
ithromycin plus ethambutol and the lack of usefulness 
of clofazimine. The specific role of rifabutin could not 
be determined from the previously noted trials. Accord- 
ingly, a clinical trial was conducted in which patients 
with MAC bacteremia all received clarithromycin and 
ethambutol and were randomly assigned to receive either 
rifabutin or a matching placebo. This study demonstrated 
no difference in either bacteriologic outcome or survival 
between the groups that did or did not receive additional 
rifabutin therapy.j5 The study results are consistent with 
the study of MAC prophylaxis in which the combination 
of clarithromycin plus rifabutin was no more effective 
than clarithromycin alone, and are possibly explained by 
the drug interaction between clarithromycin and 
rifabutin, as previously noted. Hence, the data suggest 
that there is no benefit to the addition of rifabutin to 
clarithromycin, but it remains uncertain whether better 
results could be obtained with a combination of 
azithromycin plus rifabutin, as these two drugs do not 
have a significant interaction and the combination has 
been shown to be more effective than either agent for 
MAC prophylaxis. 
Azithromycin also is active in the treatment of DMAC 
infection,56 but it has been less well studied than clar- 
ithromycin. In a small comparative tria15’ the combina- 
tion of clarithromycin plus ethambutol was more 
effective than azithromycin plus ethambutol in eradicat- 
ing MAC bacteremia. It is unknown whether adding 
rifabutin to the combination of azithromycin and etham- 
butol is of additive benefit in mycobacterial clearance, 
but this is worthy of study, since rifabutin plus azithro- 
mycin is more effective than either drug alone in MAC 
prophylaxis. 36 
There are no data currently available to guide the 
therapy of clarithromycin-resistant MAC infection. Switch- 
ing to azithromycin is not helpful, as there is complete 
cross-resistance between these two drugs.“6 Shafran et al 
found a sterilization rate of 40% among patients who 
received at least 4 weeks of rifampin, ethambutol, clo- 
fazimine, and ciprofloxacin, but that study did not con- 
tain patients with clarithromycin-resistant isolates4’ The 
substitution of rifabutin for rifampin is likely to be more 
efficacious. The use of amikacin, because of its in vitro 
activity against MAC, has been reported anecdotally, but 
there are no controlled studies of its efficacy in DMAC 
infection, and it requires parenteral administration and 
careful monitoring for nephrotoxicity and ototoxicity. 
Susceptibility testing is useful for clarithromycin.46 
In patients who have not received clarithromycin pro- 
phylaxis, clarithromycin resistance is rare.45,46,52-54,58 It is 
unclear whether it is worthwhile to perform baseline 
susceptibility testing on a routine basis. However, it is 
essential to perform clarithromycin susceptibility testing 
on isolates from patients who have failed macrolide pro- 
phylaxis or have relapsed after macrolide-based therapy. 
To date, the evidence suggests that in vitro susceptibility 
testing of MAC for nonmacrolides is not helpful.56-i8 As 
this testing is expensive and does not appear to correlate 
with clinical response to treatment, such testing cannot 
be recommended outside of a research setting. 
EFFECT OF HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY ON 
Mycobacteriunz aviurn COMPLEX 
The development of HAART has resulted in marked 
changes in the outcome of HIV disease, with significant 
reductions in hospitalizations and death as well as oppor- 
tunistic infections, including MAC.59-65 However, HAART 
does not succeed in every individual, and even among 
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those who respond initially, some experience relapse. 
Consequently, management of opportunistic infections 
remains an important part of HIV care. A unique MAC 
syndrome in AIDS patients has been described by three 
groups of investigators in the first 1 to 2 months fol- 
lowing the initiation of HAART.66-6s This syndrome con- 
sists of fever and focal MAC lymphadenitis, but in most 
cases mycobacterial blood cultures are negative. It is pos- 
tulated that this syndrome occurs in patients who already 
had subclinical MAC disease that becomes unmasked by 
HAART. A similar phenomenon has been described with 
cytomegalovirus retinitis following the initiation of 
HAART. 
A controversy that has developed following the emer- 
gence of HAART is whether it is necessary to continue 
MAC prophylaxis in individuals who formerly had CD4 
lymphocyte counts below 50 cells/mm3 but who have 
experienced a favorable response to HAART and now 
have a marked increase in their CD4 lymphocyte counts. 
There is increasing evidence to suggest that beyond the 
first 2 months of therapy, during which the unmasked 
syndrome noted above may manifest, the risk of MAC, 
and other opportunistic infections, is markedly 
reduced.61-65 Currently, clinical trials are ongoing wherein 
patients are randomized to a strategy of discontinuing 
MAC prophylaxis or continuing such prophylaxis after 
favorable responses to HAART. Until the results of such 
trials are available, arguments can be made for either 
approach. It is the practice of this author to discontinue 
MAC prophylaxis after the initiation of HAART therapy, 
provided that (1) the CD4 lymphocyte count has risen 
above 100, (2) there has been a minimal 1 log,, reduction 
in plasma HIV-RNA, and (3) the patient has received 
HAART for a minimum of 2 months. 
A related controversy is whether it is possible to dis- 
continue antimycobacterial therapy in patients who pre- 
viously had active MAC disease if they have responded to 
such therapy and they have had an excellent response to 
HAART. A small number of cases have been described in 
which antimycobacterial therapy has been successfully 
discontinued in such patients without the detection of 
relapse.70a71 This question will be difficult to study in a 
clinical trial because such a trial would be restricted to 
patients who have had DMAC infection, an excellent clin- 
ical response to antimycobacterial therapy, and an excel- 
lent response to HAART, the combination of which is 
infrequently seen in the HAART era. 
CONCLUSION 
Historically, DMAC infection has been second in inci- 
dence to PCP among HIV-related complications, with 
nearly all cases occurring at CD4 lymphocyte counts 
below 50 cells/mm3. In the era of HAART, the incidence 
of DMAC infection has fallen significantly, as has the 
incidence of other HIV-related opportunistic infections. 
Mycobacterium avium complex prophylaxis is indi- 
cated when the CD4 lymphocyte count is below 
50 cells/mm3, and azithromycin 1200 mg once weekly 
is the regimen of choice. 
The diagnosis of DMAC infection is usually estab- 
lished by mycobacterial blood cultures. Clarithromycin 
susceptibility should be tested on isolates from individ- 
uals who have failed macrolide prophylaxis, but is prob- 
ably unnecessary in the absence of prior macrolide 
therapy The initial treatment of choice is clarithromycin, 
500 mg twice daily, plus ethambutol, 15 to 20 mg/kg once 
daily. Few data exist to guide the therapy of macrolide- 
resistant strains, but the combination of rifabutin, etham- 
butol, ciprofloxacin, and clofazimine may be considered. 
Optimal antiretroviral therapy is of great importance both 
in preventing DMAC infection and in facilitating pro- 
longed bacterial clearance. 
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